187 related articles for article (PubMed ID: 34816454)
1. Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: Post hoc analysis of ALSFRS-R item scores in pivotal study MCI186-19.
Brooks BR; Pioro EP; Katz J; Takahashi F; Takei K; Zhang J; Apple S
Muscle Nerve; 2022 Feb; 65(2):180-186. PubMed ID: 34816454
[TBL] [Abstract][Full Text] [Related]
2. Associations between the ALSFRS-R score and urate levels during 12 months of edaravone treatment for amyotrophic lateral sclerosis: Post hoc analysis of ALSFRS-R scores in clinical studies MCI186-16, MCI186-17, and MCI186-19.
Takahashi F; Kano O; Nagano Y; Yoneoka T; Nelson S; Ushirogawa Y
Muscle Nerve; 2022 Nov; 66(5):593-602. PubMed ID: 36053970
[TBL] [Abstract][Full Text] [Related]
3. Associations between urate levels and amyotrophic lateral sclerosis functional score with edaravone treatment: Post hoc analysis of studies MCI186-16, MCI186-17, and MCI186-19.
Takahashi F; Kano O; Nagano Y; Yoneoka T; Nelson S; Ushirogawa Y
Muscle Nerve; 2022 Nov; 66(5):583-592. PubMed ID: 36054038
[TBL] [Abstract][Full Text] [Related]
4. Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis.
Takei K; Takahashi F; Liu S; Tsuda K; Palumbo J
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):49-54. PubMed ID: 28872913
[TBL] [Abstract][Full Text] [Related]
5. Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis.
Takahashi F; Takei K; Tsuda K; Palumbo J
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):32-39. PubMed ID: 28872914
[TBL] [Abstract][Full Text] [Related]
6. Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686].
Brooks BR; Heiman-Patterson T; Wiedau-Pazos M; Liu S; Zhang J; Apple S
PLoS One; 2022; 17(6):e0258614. PubMed ID: 35700157
[TBL] [Abstract][Full Text] [Related]
7. Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19).
Shefner J; Heiman-Patterson T; Pioro EP; Wiedau-Pazos M; Liu S; Zhang J; Agnese W; Apple S
Muscle Nerve; 2020 Feb; 61(2):218-221. PubMed ID: 31621933
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
;
Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
[TBL] [Abstract][Full Text] [Related]
9.
Palumbo JM; Hubble J; Apple S; Takei K; Tsuda K; Liu S; Zhang J; Agnese W
Amyotroph Lateral Scler Frontotemporal Degener; 2019 Aug; 20(5-6):421-431. PubMed ID: 30982356
[No Abstract] [Full Text] [Related]
10. Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trial.
Shefner JM; Jacobsen B; Kupfer S; Malik FI; Meng L; Wei J; Wolff AA; Rudnicki SA
Amyotroph Lateral Scler Frontotemporal Degener; 2024 Feb; 25(1-2):162-169. PubMed ID: 37641579
[TBL] [Abstract][Full Text] [Related]
11. Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis.
Takei K; Tsuda K; Takahashi F; Palumbo J
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):64-70. PubMed ID: 28872916
[TBL] [Abstract][Full Text] [Related]
12. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.
Witzel S; Maier A; Steinbach R; Grosskreutz J; Koch JC; Sarikidi A; Petri S; Günther R; Wolf J; Hermann A; Prudlo J; Cordts I; Lingor P; Löscher WN; Kohl Z; Hagenacker T; Ruckes C; Koch B; Spittel S; Günther K; Michels S; Dorst J; Meyer T; Ludolph AC;
JAMA Neurol; 2022 Feb; 79(2):121-130. PubMed ID: 35006266
[TBL] [Abstract][Full Text] [Related]
13. A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
EDARAVONE (MCI-186) ALS 16 STUDY GROUP
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):11-19. PubMed ID: 28872917
[TBL] [Abstract][Full Text] [Related]
14. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation).
WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):40-48. PubMed ID: 28872915
[TBL] [Abstract][Full Text] [Related]
15. Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 19 STUDY GROUP
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):55-63. PubMed ID: 28872920
[TBL] [Abstract][Full Text] [Related]
16. Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 17 STUDY GROUP
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):20-31. PubMed ID: 28872918
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis-a systematic review and meta-analysis.
Luo L; Song Z; Li X; Huiwang ; Zeng Y; Qinwang ; Meiqi ; He J
Neurol Sci; 2019 Feb; 40(2):235-241. PubMed ID: 30483992
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of edaravone in well-defined Iranian patients with amyotrophic lateral sclerosis: A parallel-group single-blind trial.
Eishi-Oskouei A; Basiri K
Curr J Neurol; 2021 Jan; 20(1):1-7. PubMed ID: 38011420
[No Abstract] [Full Text] [Related]
19. Edaravone for patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis.
Huang SL; Shen YL; Peng WY; Ye K; Zheng H
Acta Neurol Belg; 2024 Jun; 124(3):895-904. PubMed ID: 38347315
[TBL] [Abstract][Full Text] [Related]
20. Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19.
Al-Chalabi A; Chiò A; Merrill C; Oster G; Bornheimer R; Agnese W; Apple S
J Neurol Neurosurg Psychiatry; 2021 Feb; 92(2):165-171. PubMed ID: 33109706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
